Published in Curr Cancer Drug Targets on November 01, 2009
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell (2017) 1.41
The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med (2014) 0.91
Targeting hypoxic response for cancer therapy. Oncotarget (2016) 0.85
Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. J Transl Med (2012) 0.83
The mechanisms of chansu in inducing efficient apoptosis in colon cancer cells. Evid Based Complement Alternat Med (2013) 0.83
Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression. Endocrinology (2014) 0.82
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol (2014) 0.82
Toxicarioside A inhibits SGC-7901 proliferation, migration and invasion via NF-κB/bFGF signaling. World J Gastroenterol (2012) 0.80
Chansu inhibits the expression of cortactin in colon cancer cell lines in vitro and in vivo. BMC Complement Altern Med (2015) 0.77
Toxicarioside A inhibits tumor growth and angiogenesis: involvement of TGF-β/endoglin signaling. PLoS One (2012) 0.76
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology (1995) 1.62
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia (2010) 1.61
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
Identification and characterization of circulating prostate carcinoma cells. Cancer (2000) 1.41
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 1.34
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis (2012) 1.21
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther (2008) 1.16
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res (2001) 1.13
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer (2011) 1.12
Complete androgen blockade for prostate cancer: what went wrong? J Urol (2000) 1.06
Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis (2009) 1.00
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem (1999) 0.98
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol (2000) 0.93
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann Oncol (2012) 0.92
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 0.92
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res (2006) 0.91
Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry (1998) 0.90
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs (2000) 0.90
Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology (2000) 0.88
The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int (2000) 0.87
NCCN: Palliative care. Cancer Control (2001) 0.85
Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. Int J Oncol (1998) 0.83
Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Invest (2000) 0.83
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.83
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2001) 0.80
Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology (1999) 0.77
NCCN: New chemotherapeutic approaches to hormone refractory prostate cancer. Cancer Control (2001) 0.77
Renal, bladder, and prostate cancers: gene therapy. Cancer Treat Res (1996) 0.75
Adjuvant chemotherapy for T3 prostate cancer: not ready for prime time. Urology (2000) 0.75
Nutritional status of long-term patients in the acute care setting. Intern Med J (2012) 0.75